Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary

Microvascular Perfusion Sonographic Imaging to Detect Early Stage Ovarian Cancer

RATIONALE: New diagnostic procedures, such as contrast-enhanced ultrasonography, may be an effective method of finding ovarian cancer.

PURPOSE: This clinical trial is studying how well contrast-enhanced ultrasonography works in diagnosing early-stage ovarian cancer in patients with an adnexal mass undergoing surgery to remove the ovary.

OBJECTIVES:

• Determine whether use of a contrast agent improves the images of the ovaries during ultrasonography.

OUTLINE: This is a multicenter study.

Patients may undergo baseline transabdominal or transvaginal ultrasonography, if not already done. Patients then undergo contrast-enhanced transabdominal or transvaginal ultrasonography using perflutren lipid microspheres (Definity®) IV.

Pathology reports from tissue collected during subsequent oophorectomy is analyzed and compared with ultrasonography findings.

DISEASE CHARACTERISTICS:

• Diagnosis of adnexal mass
• Scheduled to undergo surgical oophorectomy

PATIENT CHARACTERISTICS:

• Not pregnant or nursing
• Negative pregnancy test
• No known respiratory failure as manifested by signs and symptoms of carbon dioxide retention or hypoxemia
• No pulmonary vasculitis
• No known history of severe emphysema
• No known history of pulmonary emboli
• No other condition that causes pulmonary hypertension due to compromised pulmonary arterial vasculature
• No known history of severe pulmonary hypertension (i.e., systolic pulmonary artery pressures > 90 mm Hg)
• No known history of congenital heart defect that creates a bidirectional or right-to-left shunt
• No worsening or clinically unstable congestive heart failure
• No known acute myocardial infarction or acute coronary syndromes
• No known serious ventricular arrhythmias
• Not at high risk for arrhythmia due to prolongation of the QT interval
• No known or suspected hypersensitivity to blood, blood products, or albumin
• No known hypersensitivity to perflutren
• No known or suspected hypersensitivity to octafluoropropane or any other ingredients of perflutren lipid microspheres (Definity®)
• No mental status problems, illiteracy, or other circumstance that would preclude giving informed consent

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics